Dyadic International, Inc. (DYAI) Stock Price

DYAIStock

$0.41−60.85%52W

Market Cap$16.47M

P/E—

PEG Ratio—

Div yield—

Beta1.10

DYAI Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-62.65%

Price vs S&P 500 (4W)3.84%

VGM Score36.87

Book Value / Share (Quarterly)$0.03

P/TBV (Annual)25.52x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)1.79%

Cash Flow / Share (Quarterly)$-0.20

Price vs S&P 500 (YTD)-68.19%

Gross Margin (TTM)16.24%

Net Profit Margin (TTM)-200.46%

EPS (TTM)$-0.23

10-Day Avg Trading Volume0.11M

EPS Excl Extra (TTM)$-0.23

Revenue Growth (5Y)14.07%

EPS (Annual)$-0.23

ROI (Annual)-117.67%

Gross Margin (Annual)24.93%

Net Profit Margin (5Y Avg)-303.18%

Cash / Share (Quarterly)$0.09

Revenue Growth QoQ (YoY)-0.57%

ROA (Last FY)-74.05%

Revenue Growth TTM (YoY)-8.05%

EBITD / Share (TTM)$-0.22

ROE (5Y Avg)-221.45%

Operating Margin (TTM)-195.10%

Cash Flow / Share (Annual)$-0.16

P/B Ratio13.36x

P/B Ratio (Quarterly)27.60x

Net Income / Employee (Annual)$-1,227,400

EV / Revenue (TTM)5.28x

Net Interest Coverage (TTM)-32.67x

ROA (TTM)-84.77%

EV / EBITDA (TTM)69.26x

EPS Incl Extra (Annual)$-0.23

Current Ratio (Annual)2.68x

Quick Ratio (Quarterly)1.54x

3-Month Avg Trading Volume0.20M

52-Week Price Return-60.85%

Revenue / Employee (TTM)$633,700

Tangible BV / Share (Quarterly)$0.02

P/S Ratio (Annual)5.33x

Asset Turnover (Annual)0.31x

52-Week High$1.60

Operating Margin (5Y Avg)-321.89%

EPS Excl Extra (Annual)$-0.23

Tangible BV CAGR (5Y)-31.65%

26-Week Price Return-52.75%

Quick Ratio (Annual)2.62x

13-Week Price Return-67.37%

Total Debt / Equity (Annual)4.08x

Current Ratio (Quarterly)1.65x

Enterprise Value$20.09M

Revenue / Share Growth (5Y)10.23%

Asset Turnover (TTM)0.42x

Book Value / Share Growth (5Y)-49.46%

Revenue / Employee (Annual)$515,100

Inventory Turnover (Annual)3.49x

Pretax Margin (Annual)-238.31%

Cash / Share (Annual)$0.20

3-Month Return Std Dev89.51%

Gross Margin (5Y Avg)33.88%

Net Income / Employee (TTM)$-1,270,300

ROE (Last FY)-597.58%

Net Interest Coverage (Annual)-32.65x

EPS Basic Excl Extra (Annual)$-0.23

P/FCF (TTM)11.36x

Receivables Turnover (TTM)3.77x

Total Debt / Equity (Quarterly)4.08x

EPS Incl Extra (TTM)$-0.23

Receivables Turnover (Annual)4.66x

ROI (TTM)-84.44%

P/S Ratio (TTM)4.33x

Pretax Margin (5Y Avg)-303.18%

Revenue / Share (Annual)$0.09

Tangible BV / Share (Annual)$0.06

Price vs S&P 500 (52W)-76.38%

Year-to-Date Return-56.27%

5-Day Price Return-2.37%

EPS Normalized (Annual)$-0.23

ROA (5Y Avg)-69.53%

Net Profit Margin (Annual)-238.31%

Month-to-Date Return-7.53%

EBITD / Share (Annual)$-0.22

Operating Margin (Annual)-232.75%

LT Debt / Equity (Annual)4.08x

ROI (5Y Avg)-94.03%

LT Debt / Equity (Quarterly)4.08x

EPS Basic Excl Extra (TTM)$-0.23

P/TBV (Quarterly)84.50x

P/B Ratio (Annual)27.60x

Inventory Turnover (TTM)0.51x

Pretax Margin (TTM)-200.46%

Book Value / Share (Annual)$0.03

Price vs S&P 500 (13W)-70.06%

Beta1.10x

P/FCF (Annual)3.51x

Revenue / Share (TTM)$0.10

ROE (TTM)-350.86%

52-Week Low$0.34

vGradeD

gGradeC

mGradeD

vgmGradeD

DYAI Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 12, 2026	-$0.04	-$0.06	-63.62%(-$0.02)
Q1 2026	May 13, 2026	-$0.04	-$0.05	-11.11%(-$0.01)
Q4 2025	Mar 25, 2026	-$0.04	-$0.06	-33.33%(-$0.02)
Q3 2025	Nov 12, 2025	-$0.04	-$0.06	-38.47%(-$0.02)
Q2 2025	Aug 13, 2025	-$0.06	-$0.06	+0.00%(+$0.00)

DYAI Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.14

Industry Peers — Biological Products(186)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
DYAIDyadic International, Inc.	D	C	D	4.3x	-8.1%	16.2%	—	$0.41
AMGNAmgen Inc	D	C	A	6.1x	9.1%	74.3%	2.9%	$432.49
GILDGilead Sciences Inc	C	B	A	6.4x	5.5%	79.6%	133.6%	$156.19
MRNAModerna, Inc. Common Stock	F	C	A	39.1x	-27.6%	36.4%	—	$218.01
ARGXargenx SE American Depositary Shares	D	A	B	6.6x	165.2%	89.8%	—	$819.14
RVMDRevolution Medicines, Inc. Common Stock	F	—	B	3296.2x	—	—	—	$177.96
BIIBBiogen Inc. Common Stock	C	D	A	3.4x	0.3%	74.0%	-18.8%	$232.65
BNTXBioNTech SE American Depositary Share	C	C	C	7.6x	-11.8%	79.2%	—	$87.71
EXELExelixis Inc	C	B	A	6.3x	9.2%	96.5%	31.1%	$62.23
HALOHalozyme Therapeutics, Inc.	D	B	A	8.3x	41.1%	82.4%	22.9%	$121.84
NBIXNeurocrine Biosciences Inc	C	B	B	4.1x	34.4%	98.0%	2.3%	$135.71
TECHBio-Techne Corp.	D	C	B	9.4x	-0.4%	66.2%	6.0%	$72.57
RGENRepligen Corp	F	C	A	14.2x	16.5%	53.8%	-4.9%	$175.42
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	—	—	—	—	$135.07
PCVXVaxcyte, Inc. Common Stock	—	—	B	—	—	—	—	$63.62
IBRXImmunityBio, Inc. Common Stock	F	A	A	58.7x	192.9%	99.3%	—	$9.18
QGENQIAGEN N.V.	C	C	B	4.5x	3.0%	62.5%	4.2%	$46.13
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	21.3x	22.6%	94.6%	—	$316.58
TWSTTwist Bioscience Corporation Common Stock	D	B	A	20.2x	19.2%	52.0%	—	$132.75
KYMRKymera Therapeutics, Inc. Common Stock	F	B	B	83.0x	134.8%	—	—	$104.78
IOVAIovance Biotherapeutics, Inc. Common Stock	D	B	A	19.0x	34.5%	48.4%	—	$13.62
IMVTImmunovant, Inc. Common Stock	—	—	C	—	—	—	—	$26.73
KODKodiak Sciences Inc Common Stock	—	—	A	—	—	—	—	$85.75
CGONCG Oncology, Inc. Common stock	F	A	B	851.8x	1030.3%	-85.2%	—	$59.85
SRRKScholar Rock Holding Corporation Common Stock	F	—	C	102.7x	—	—	—	$39.90
CRSPCRISPR Therapeutics AG	D	B	B	355.6x	-64.8%	—	—	$49.25
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	B	12.4x	50.1%	75.6%	—	$24.02
RLAYRelay Therapeutics, Inc. Common Stock	F	D	B	344.7x	23.9%	—	—	$16.28
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	5.5x	105.2%	93.3%	—	$68.07
DNLIDenali Therapeutics Inc. Common Stock	F	—	C	781.1x	—	—	—	$17.61
BEAMBeam Therapeutics Inc. Common Stock	D	B	C	15.5x	158.9%	—	—	$23.47
ADMAADMA Biologics, Inc.	C	C	B	4.7x	8.0%	64.7%	—	$10.68
VCELVericel Corporation	D	B	B	6.7x	22.9%	74.6%	38.9%	$40.13
BCRXBioCryst Pharmaceuticals Inc	B	A	B	2.1x	68.7%	97.8%	—	$7.79
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	33.9x	-15.1%	3.5%	—	$3.46
NVAXNovavax Inc	C	D	B	4.5x	-61.6%	79.2%	—	$11.26
ALVOAlvotech Ordinary Shares	D	D	B	3.9x	-12.1%	60.7%	—	$5.00
MESOMesoblast Limited American Depositary Shares	D	A	C	14.6x	599.2%	86.1%	—	$13.28
VIRVir Biotechnology, Inc. Common Stock	B	B	B	5.6x	1496.1%	100.0%	—	$9.96
MAZEMaze Therapeutics, Inc. Common Stock	—	A	B	—	700.0%	—	—	$27.53
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	3.5x	20.9%	98.9%	—	$29.40
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	C	—	—	—	—	$30.07
INBXInhibrx Biosciences, Inc. Common Stock	D	C	A	944.3x	550.0%	—	—	$89.83
TSHATaysha Gene Therapies, Inc. Common Stock	D	C	D	120.7x	-32.3%	—	—	$3.62
IMTXImmatics N.V. Ordinary Shares	C	C	C	21.5x	-68.0%	—	—	$6.73
REPLReplimune Group, Inc.	—	—	B	—	—	—	—	$10.86
VORVor Biopharma Inc. Common Stock	—	—	C	—	—	—	—	$18.03
MGTXMeiraGTx Holdings plc Ordinary Shares	C	A	C	2.2x	948.4%	98.0%	—	$9.28
SLBTSL Science Holding Limited Ordinary Shares	—	—	D	—	—	—	—	$1.53
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	C	—	—	—	—	$12.93
GLUEMonte Rosa Therapeutics, Inc. Common Stock	D	F	D	28.9x	-83.9%	—	—	$9.74

About Dyadic International, Inc.

Dyadic International is a biotechnology company that develops and licenses a gene expression platform based on the C1 fungus (Thermothelomyces heterothallica) for producing industrial enzymes and proteins. The company generates recurring revenue through technology licensing agreements with major industrial partners including BASF, Abengoa Bioenergy, and Codexis for non-pharmaceutical applications.